Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.

doi:10.1200/JCO.19.01406

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Feb 2020

Schlenk Richard F, Paschka Peter, Krzykalla Julia, Weber Daniela, Kapp-Schwoerer Silke, Gaidzik Verena I, Leis Claudia, Fiedler Walter, Kindler Thomas, Schroeder Thomas, Mayer Karin, Lübbert Michael, Wattad Mohammed, Götze Katharina, Horst Heinz A, Koller Elisabeth, Wulf Gerald, Schleicher Jan, Bentz Martin, Greil Richard, Hertenstein Bernd, Krauter Jürgen, Martens Uwe, Nachbaur David, Abu Samra Maisun, Girschikofsky Michael, Basara Nadezda, Benner Axel, Thol Felicitas, Heuser Michael, Ganser Arnold, Döhner Konstanze, Döhner Hartmut

Abstract excerpt

PURPOSE: High CD33 expression in acute myeloid leukemia (AML) with mutated NPM1 provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity. We conducted a randomized trial to evaluate GO in combination with intensive induction and consolidation therapy in NPM1-mutated AML. PATIENTS AND METHODS: Between May 2010 and September 2017, patients ≥ 18 years old and considered eligible for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Cytarabine

Share to Etoposide

Share to Induction Chemotherapy

Share to Nucleophosmin

Share to Progression-Free Survival

Share to Tretinoin

Source

Open in PubMed Open full text

Identifiers

PMID: 31851556
DOI: 10.1200/JCO.19.01406
PMCID: PMC7030890

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.PMID 31851556Read ↗

High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.Semantic proximity Read ↗

Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.Semantic proximity Read ↗

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.Semantic proximity Read ↗

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.Semantic proximity Read ↗

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia TreatmentSemantic proximity Read ↗

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.Semantic proximity Read ↗

Gemtuzumab ozogamicin in acute myeloid leukemia.Semantic proximity Read ↗

ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.Semantic proximity Read ↗

Intermediate-risk acute myeloid leukemia therapy: current and future.Semantic proximity Read ↗

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.Semantic proximity Read ↗

Prognostic Relevance of NPM1 and FLT3 Mutations in Acute Myeloid Leukaemia, Longterm Follow-Up—A Single Center ExperienceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.